37-327

DRUG EFFICACY

Printed for the use of the Committee on Government Operations

FLORENCE P. DWYER, New Jersey
CLARENCE J. BROWN, Ohio
GUY VANDER JAGT, Michigan

DELPHIS C. GOLDBERG, Professional Staff Member
W. DONALD GRAY, Senior Investigator

JAMES R. NAUGHTON, Counsel
ROBERT S. MCCLEERY, Consultant

Brown, Hon. Garry, a Representative in Congress, from the State of

Michigan.

Ley, Dr. Herbert L., Jr., Commissioner, Food and Drug Administra-

tion, Department of Health, Education, and Welfare; accompanied

by Winton B. Rankin, Deputy Commissioner, FDA; J. Kenneth

Kirk, Associate Commissioner for Compliance; William W. Good-

rich, Assistant General Counsel, HEW; Dr. John J. Jennings,

Acting Director, Bureau of Medicine; and Dr. David Lidd, Bureau

of Medicine..

Letters, statements, etc., submitted for the record by-

Page

173-

227

333

333

178, 227, 351

Fountain, Hon. L. H., a Representative in Congress from the State

of North Carolina, and chairman, Intergovernmental Relations

Subcommittee:

Correspondence and memorandum re FDA's delay in granting

the subcommittee staff certain drug files for review prior to the

hearings__

175

Letter from Representative Garry Brown of Michigan re action

concerning the Upjohn Co., and its drug Panalba dated May

14, 1969.

331

Memorandums and correspondence concerning Panalba, Alba-

mycin, and novobiocin dated:

April 29, 1969.

179

April 30, 1969.

181

May 1, 1969

183

May 5, 1969.

185

May 6, 1969-

187

May 9, 1969_

200

Miscellaneous correspondence re Panalba received by the sub-
committee subsequent to the conclusion of the hearings.
Sundry studies re Serc and certain side effects (Meniere's syn-
drome).

Gray, W. Donald, senior investigator, Intergovernmental Relations

Subcommittee:

413

301

FDA summary of the Upjohn Co.'s records concerning studies
which they had done on Panalba over a certain period of time.

220